{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID-19+Severe+Pneumonia&page=4", "query": { "condition": "COVID-19 Severe Pneumonia", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 271, "total_pages": 28, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID-19+Severe+Pneumonia&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID-19+Severe+Pneumonia&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T20:33:58.508Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04359810", "title": "Plasma Therapy of COVID-19 in Severely Ill Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "SARS-CoV-2 Infection" ], "interventions": [ { "name": "Convalescent Plasma (anti-SARS-CoV-2 plasma)", "type": "BIOLOGICAL" }, { "name": "Non-convalescent Plasma (control plasma)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Max O'Donnell", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 223, "start_date": "2020-04-21", "completion_date": "2020-12-30", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-22T20:33:58.508Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04359810" }, { "nct_id": "NCT04878055", "title": "Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumonia, Viral" ], "interventions": [ { "name": "Reparixin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Dompé Farmaceutici S.p.A", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 287, "start_date": "2021-02-14", "completion_date": "2021-10-31", "has_results": true, "last_update_posted_date": "2024-06-13", "last_synced_at": "2026-10-22T20:33:58.508Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Greenwood, Indiana", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Greenwood", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04878055" }, { "nct_id": "NCT04646603", "title": "MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19", "ARDS, Human", "Stem Cells", "Regeneration" ], "interventions": [ { "name": "MRG-001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedRegen LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-12-01", "completion_date": "2022-07-01", "has_results": false, "last_update_posted_date": "2022-02-15", "last_synced_at": "2026-10-22T20:33:58.508Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04646603" }, { "nct_id": "NCT04518410", "title": "ACTIV-2: A Study for Outpatients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Coronavirus", "Covid19" ], "interventions": [ { "name": "bamlanivimab 7000mg", "type": "BIOLOGICAL" }, { "name": "BRII-196+BRII-198", "type": "BIOLOGICAL" }, { "name": "AZD7442 (IV)", "type": "BIOLOGICAL" }, { "name": "AZD7442 (IM)", "type": "BIOLOGICAL" }, { "name": "SNG001", "type": "DRUG" }, { "name": "Camostat", "type": "DRUG" }, { "name": "BMS-986414 + BMS-986413", "type": "BIOLOGICAL" }, { "name": "SAB-185 (3,840 Units/kg)", "type": "BIOLOGICAL" }, { "name": "SAB-185 (10,240 Units/kg)", "type": "BIOLOGICAL" }, { "name": "CASIRIVIMAB + IMDEVIMAB", "type": "DRUG" }, { "name": "Placebo for Bamlanivimab 7000mg", "type": "DRUG" }, { "name": "Placebo for Bamlanivimab 700mg", "type": "DRUG" }, { "name": "Placebo for BRII-196+BRII-198", "type": "DRUG" }, { "name": "Placebo for SNG001", "type": "DRUG" }, { "name": "Placebo for Camostat", "type": "DRUG" }, { "name": "Placebo for SAB-185 (low dose)", "type": "DRUG" }, { "name": "Placebo for BMS-986414 + BMS-986413", "type": "DRUG" }, { "name": "Placebo for AZD7442 (IV)", "type": "DRUG" }, { "name": "Placebo for AZD7442 (IM)", "type": "DRUG" }, { "name": "Placebo for SAB-185 (high dose)", "type": "DRUG" }, { "name": "bamlanivimab 700mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4044, "start_date": "2020-08-19", "completion_date": "2023-06-20", "has_results": true, "last_update_posted_date": "2024-08-02", "last_synced_at": "2026-10-22T20:33:58.508Z", "location_count": 207, "location_summary": "Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04518410" }, { "nct_id": "NCT05487040", "title": "A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "PF-07321332 (nirmatrelvir)/ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2022-09-07", "completion_date": "2023-07-11", "has_results": true, "last_update_posted_date": "2024-09-23", "last_synced_at": "2026-10-22T20:33:58.508Z", "location_count": 52, "location_summary": "Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05487040" }, { "nct_id": "NCT04448145", "title": "Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "COVID-19", "Corona Virus Infection", "SARS-CoV 2" ], "interventions": [], "intervention_types": [], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 800, "start_date": "2020-03-26", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-22T20:33:58.508Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04448145" }, { "nct_id": "NCT04540185", "title": "A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19", "SARS (Severe Acute Respiratory Syndrome)", "SARS-CoV Infection", "SARS-CoV-2" ], "interventions": [ { "name": "Biological: oral polio vaccine", "type": "BIOLOGICAL" }, { "name": "Comparable Placebo", "type": "BIOLOGICAL" }, { "name": "NA-831", "type": "DRUG" }, { "name": "Comparable Placebo of drug", "type": "DRUG" }, { "name": "Combination of oral polio vaccine and NA-831", "type": "COMBINATION_PRODUCT" }, { "name": "Comparable Placebo of Oral Polio Vaccine and Placebo of drug", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Biomed Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3600, "start_date": "2020-11-01", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-10-22T20:33:58.508Z", "location_count": 8, "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Sunnyvale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04540185" }, { "nct_id": "NCT04388527", "title": "COVID-19 Convalescent Plasma for Mechanically Ventilated Population", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Covid-19" ], "interventions": [ { "name": "COVID-19 Convalescent Plasma", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2020-04-30", "completion_date": "2021-01-30", "has_results": true, "last_update_posted_date": "2022-04-04", "last_synced_at": "2026-10-22T20:33:58.508Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04388527" }, { "nct_id": "NCT05541861", "title": "Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "SARS-CoV-2 Infection", "COVID-19" ], "interventions": [ { "name": "BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg", "type": "BIOLOGICAL" }, { "name": "BNT162b4 5 mcg", "type": "BIOLOGICAL" }, { "name": "BNT162b4 10 mcg", "type": "BIOLOGICAL" }, { "name": "BNT162b4 15 mcg", "type": "BIOLOGICAL" }, { "name": "BNT162b4 30 mcg", "type": "BIOLOGICAL" }, { "name": "BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 383, "start_date": "2022-11-08", "completion_date": "2024-11-22", "has_results": true, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-22T20:33:58.508Z", "location_count": 17, "location_summary": "Tempe, Arizona • Newport Beach, California • San Diego, California + 13 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Milford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05541861" }, { "nct_id": "NCT04366791", "title": "Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pneumonia", "Coronavirus Infection in 2019 (COVID-19)", "Severe Acute Respiratory Syndrome (SARS) Pneumonia" ], "interventions": [ { "name": "Low Dose Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2020-04-24", "completion_date": "2022-03-11", "has_results": false, "last_update_posted_date": "2022-03-29", "last_synced_at": "2026-10-22T20:33:58.508Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04366791" } ] }